A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT ID: NCT02604836
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1711 participants
INTERVENTIONAL
2004-06-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ibandronate
Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
Ibandronate
Film-coated oral ibandronate tablet (150 mg) once-monthly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibandronate
Film-coated oral ibandronate tablet (150 mg) once-monthly
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hypersensitivity to bisphosphonates
* Inability to swallow a tablet whole
* Malignant disease diagnosed within previous 10 years (except resected basal cell cancer).
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_CHAIR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Columbiana, Alabama, United States
Huntsville, Alabama, United States
Mobile, Alabama, United States
Montgomery, Alabama, United States
Chandler, Arizona, United States
Gilbert, Arizona, United States
Paradise Valley, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
Tucson, Arizona, United States
Carlisle, Arkansas, United States
Jonesboro, Arkansas, United States
Little Rock, Arkansas, United States
Pine Bluff, Arkansas, United States
Rogers, Arkansas, United States
Searcy, Arkansas, United States
Sherwood, Arkansas, United States
Anaheim, California, United States
Beverly Hills, California, United States
Laguna Hills, California, United States
Mission Viejo, California, United States
Palm Desert, California, United States
Palo Alto, California, United States
Sacramento, California, United States
San Diego, California, United States
Tacoma, California, United States
Vista, California, United States
Westlake Village, California, United States
Colorado Springs, Colorado, United States
Lakewood, Colorado, United States
Avon, Connecticut, United States
Cromwell, Connecticut, United States
Hamden, Connecticut, United States
New London, Connecticut, United States
Waterbury, Connecticut, United States
Wilmington, Delaware, United States
Aventura, Florida, United States
Clearwater, Florida, United States
DeLand, Florida, United States
Fort Myers, Florida, United States
Gainesville, Florida, United States
Gainesville, Florida, United States
Longwood, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Ocala, Florida, United States
Palm Bay, Florida, United States
Palm Harbor, Florida, United States
Port Orange, Florida, United States
Sarasota, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Decatur, Georgia, United States
Rome, Georgia, United States
Boise, Idaho, United States
Coeur d'Alene, Idaho, United States
Champaign, Illinois, United States
Creve Coeur, Illinois, United States
Peoria, Illinois, United States
Evansville, Indiana, United States
Arkansas City, Kansas, United States
Newton, Kansas, United States
Wichita, Kansas, United States
Natchitoches, Louisiana, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Bethesda, Maryland, United States
Chelsea, Michigan, United States
Detroit, Michigan, United States
Saint Joseph, Michigan, United States
Chaska, Minnesota, United States
Jefferson City, Missouri, United States
Kansas City, Missouri, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
Omaha, Nebraska, United States
Clifton, New Jersey, United States
Middletown, New Jersey, United States
New Brunswick, New Jersey, United States
Princeton, New Jersey, United States
Brooklyn, New York, United States
East Syracuse, New York, United States
New York, New York, United States
Olean, New York, United States
Rochester, New York, United States
Stony Brook, New York, United States
Durham, North Carolina, United States
Durham, North Carolina, United States
Fayetteville, North Carolina, United States
Morehead City, North Carolina, United States
Morganton, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
Fargo, North Dakota, United States
Grand Forks, North Dakota, United States
Beachwood, Ohio, United States
Canfield, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Medford, Oregon, United States
Portland, Oregon, United States
Bala-Cynwyd, Pennsylvania, United States
Langhorne, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
Charleston, South Carolina, United States
Mt. Pleasant, South Carolina, United States
Spartanburg, South Carolina, United States
Bristol, Tennessee, United States
Memphis, Tennessee, United States
Murfreesboro, Tennessee, United States
Nashville, Tennessee, United States
Sevierville, Tennessee, United States
Carrollton, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Denton, Texas, United States
San Antonio, Texas, United States
Wichita Falls, Texas, United States
Norfolk, Virginia, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Renton, Washington, United States
Seattle, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Tacoma, Washington, United States
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML18056
Identifier Type: -
Identifier Source: org_study_id